[go: up one dir, main page]

WO2004005540A3 - Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen - Google Patents

Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen Download PDF

Info

Publication number
WO2004005540A3
WO2004005540A3 PCT/DE2003/001986 DE0301986W WO2004005540A3 WO 2004005540 A3 WO2004005540 A3 WO 2004005540A3 DE 0301986 W DE0301986 W DE 0301986W WO 2004005540 A3 WO2004005540 A3 WO 2004005540A3
Authority
WO
WIPO (PCT)
Prior art keywords
ngal
diagnosis
treatment
binding substances
cancer diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2003/001986
Other languages
English (en)
French (fr)
Other versions
WO2004005540A2 (de
Inventor
Gunda Herberth
Edgar Dahl
Katrin Sparbier
Anke Stein
Esmeralda Heiden
Irina Klamann
Stafan Taudien
Andreas Rump
Rosemarie Lichtner
Bernd Hinzmann
Andre Rosenthal
Thomas Specht
Christian Pilarsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003245858A priority Critical patent/AU2003245858A1/en
Publication of WO2004005540A2 publication Critical patent/WO2004005540A2/de
Publication of WO2004005540A3 publication Critical patent/WO2004005540A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die Erfindung betrifft Verwendungen von Ngal zur Diagnose und Behandlung von Krebs sowie zum Screenen nach Substan­zen für solche Zwecke.
PCT/DE2003/001986 2002-07-02 2003-06-12 Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen Ceased WO2004005540A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003245858A AU2003245858A1 (en) 2002-07-02 2003-06-12 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10230631A DE10230631A1 (de) 2002-07-02 2002-07-02 Verwendungen von an Ngal bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
DE10230631.1 2002-07-02

Publications (2)

Publication Number Publication Date
WO2004005540A2 WO2004005540A2 (de) 2004-01-15
WO2004005540A3 true WO2004005540A3 (de) 2004-09-16

Family

ID=29761726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/001986 Ceased WO2004005540A2 (de) 2002-07-02 2003-06-12 Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen

Country Status (3)

Country Link
AU (1) AU2003245858A1 (de)
DE (1) DE10230631A1 (de)
WO (1) WO2004005540A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274104A1 (en) * 2005-02-10 2008-11-06 Arlinghaus Ralph B Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics
WO2008030370A1 (en) * 2006-09-05 2008-03-13 Beth Israel Deaconess Medical Center, Inc. Use of lipocalin 2 in the regulation of insulin sensitivity
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
JP5746861B2 (ja) * 2007-10-19 2015-07-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 哺乳動物のｎｇａｌに結合する抗体及びその使用
CA2742291A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, andmethods of enrichment, analysis and use
GB201016852D0 (en) * 2010-10-07 2010-11-17 Univ York Cell differentiation
CN109709340B (zh) * 2018-12-29 2022-02-11 江苏众红生物工程创药研究院有限公司 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030907A1 (en) * 1997-01-06 1998-07-16 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
WO1999053040A2 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus ovartumorgewebe
WO2002024866A2 (en) * 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
AU2608201A (en) * 1999-12-30 2001-07-16 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030907A1 (en) * 1997-01-06 1998-07-16 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
WO1999053040A2 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus ovartumorgewebe
WO2002024866A2 (en) * 2000-09-21 2002-03-28 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTSCH S ET AL: "CLONING AND EXPRESSION OF HUMAN NEUTROPHIL LIPOCALIN CDNA DERIVED FROM BONE MARROW AND OVARIAN CANCER CELLS", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 357, 1995, pages 255 - 259, XP002061582, ISSN: 0014-5793 *
COWLAND J B ET AL: "MOLECULAR CHARACTERIZATION AND PATTERN OF TISSUE EXPRESSION OF THE GENE FOR NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN FROM HUMANS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 45, 1997, pages 17 - 23, XP002909708, ISSN: 0888-7543 *
DATABASE GENESEQ [online] EBI; 27 December 2002 (2002-12-27), MACK AND GISH: "Detecting an ovarian cancer-associated transcript in a cell from a patient, comprises contacting a biological sample from the patient with a polynucleotide that hybridizes to an ovarian cancer gene", XP002271024, Database accession no. ADB80594 *
DATABASE GENESEQ [online] EBI; 3 January 2002 (2002-01-03), BIRSE ET AL.: "Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovariancancer), immune disorders, cardiovascular disorders and neurological diseases", XP002271022, Database accession no. ABP41113 *
DATABASE GENESQ [online] EBI; 19 September 2002 (2002-09-19), MONAHAN ET AL.: "Assessing whether a patient is afflicted with ovarian cancer, useful in assessing the stage or progression of the disease, comprises comparing the expression level of a cancer marker in a sample from a patient and from a non cancer patient", XP002271023, Database accession no. ABG96361 *
FRIEDL A ET AL: "NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN IN NORMAL AND NEOPLASTIC HUMAN TISSUES. CELL TYPE-SPECIFIC PATTERN OF EXPRESSION", THE HISTOCHEMICAL JOURNAL, LONDON, GB, vol. 31, 1999, pages 433 - 441, XP002909707 *
STOESZ S P ET AL: "HETEROGENEOUS EXPRESSION OF THE LIPOCALIN NGAL IN PRIMARY BREAST CANCERS", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 79, 1998, pages 565 - 572, XP000979576, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
AU2003245858A8 (en) 2004-01-23
WO2004005540A2 (de) 2004-01-15
AU2003245858A1 (en) 2004-01-23
DE10230631A1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003293460A1 (en) Novel application of biosensors for diagnosis and treatment of disease
WO2003087831A3 (en) Proteins involved in breast cancer
EP1572091A3 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004071382A3 (en) Substituted heterocycles
AU2003290605A1 (en) Compositions and methods for the diagnosis and treatment of sepsis
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
AU2003294324A1 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP